ELOVL6-IN-4 is a potent and selective long chain fatty acid elongase 6 (ELOVL6) inhibitor that is orally active, with IC50 values of 79 nM for human ELOVL6 and 94 nM for mouse ELOVL6. It demonstrates excellent selectivity over other human ELOVL subtypes (ELOVL1, -2, -3, and -5) and mouse ELOVL3 [1].

ELOVL6-IN-4 (compound 1w) effectively reduces the elongation index in mouse hepatocytes H2.35, with an IC₅₀ of 30 nM.

ELOVL6-IN-4 (compound 1w; 1-10 mg/kg; oral administration, single dose) effectively and dose-dependently inhibits the elongation index in the liver of male C57BL/6J mice [1]. Dosage: 1 mg/kg, 3 mg/kg, and 10 mg/kg; Administration: Oral, single dose. Result: Significant inhibition of hepatic elongation index.